Qiagen N.V. Stock News

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

Brazilian meat giant BRF is negotiating with Qatar Investment Authority (QIA), its joint venture partner in the ownership of Turkey-based Read More... The post BRF seeking to take full control of Turkey-based poultry processor Banvit appeared first on Just Food .

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

Brokerages predict that QIAGEN (NYSE:QGEN) will report sales of $526.28 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for QIAGENs earnings. The highest sales estimate is $537.10 million and the lowest is $515.80 million. QIAGEN posted sales of $571.23 million in the same quarter last year, which suggests a []

The global Point of Care Reader market size is expected a CAGR of 9.1% during 2021-2027. The glucose checking unit section overwhelms the worldwide Point of Care Reader market. Glucose checking gadgets are utilized to gauge the measure of glucose

Kepler Capital Markets lowered shares of QIAGEN (NYSE:QGEN) to a hold rating in a research report sent to investors on Friday, PriceTargets.com reports. Kepler Capital Markets currently has $49.00 price objective on the stock. Several other research firms have also weighed in on QGEN. Redburn Partners initiated coverage on QIAGEN in a research report on []

(RTTNews) - QIAGEN (QGEN) and DiaSorin said Monday that the U.S. Food and Drug Administration has approved the LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin''s automated LIAISON XS platform. The company noted that the approval widens the accessibility of U.S. customers to automation solutions for processing QIAGEN''s blood-based test

Additional U.S. approval for LIAISON XS platform builds on FDA approval in 2019 for QuantiFERON assay running on DiaSorin''s LIAISON XL analyzer Collaboration now provides full range of automation

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced that the U.S. Food and Drug Administration (FDA) has a

HILDEN, Germany & GERMANTOWN, Maryland--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new variant of concern detected in South Africa. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against the genetic mutations of the variant, which is known by its scientific name, B.1.1.529. The assessment was made again

Overview: Cell lysis is a key step for research or study in proteomics as the extraction of protein depends on the cell lysis. It is an important step that is needed to perform nuclear extraction, after which using recombinant DNA technology

Qiagen N.V. (NYSE:QGEN) announced that its polymerase chain reaction (PCR) tests remain accurate and effective in detecting COVID-19 infections in light of the emergence of a new variant detected i

Global Neurological Biomarkers Market Synopsis: By employing an exceptional Neurological Biomarkers Market report, businesses can get details about market drivers and market restraints which help them to take presumption about reducing or growing the production of particular product. When globalization is

Wells Fargo & Company MN raised its holdings in QIAGEN (NYSE:QGEN) by 0.9% during the second quarter, Holdings Channel reports. The institutional investor owned 580,613 shares of the companys stock after buying an additional 5,246 shares during the period. Wells Fargo & Company MNs holdings in QIAGEN were worth $28,089,000 as of its most recent []